Achieve Life Sciences Inc (NASDAQ:ACHV) Expected to Announce Earnings of -$0.22 Per Share

Wall Street brokerages forecast that Achieve Life Sciences Inc (NASDAQ:ACHV) will announce earnings of ($0.22) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Achieve Life Sciences’ earnings. Achieve Life Sciences posted earnings per share of ($0.71) in the same quarter last year, which indicates a positive year-over-year growth rate of 69%. The business is expected to issue its next earnings results on Wednesday, November 6th.

According to Zacks, analysts expect that Achieve Life Sciences will report full year earnings of ($1.60) per share for the current year, with EPS estimates ranging from ($1.83) to ($1.36). For the next financial year, analysts expect that the company will report earnings of ($1.49) per share, with EPS estimates ranging from ($1.82) to ($1.16). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Achieve Life Sciences.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.17).

A number of brokerages recently weighed in on ACHV. Maxim Group reissued a “buy” rating and set a $6.00 price objective on shares of Achieve Life Sciences in a report on Tuesday, October 1st. ValuEngine raised Achieve Life Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Finally, LADENBURG THALM/SH SH reissued a “buy” rating and set a $20.00 price objective on shares of Achieve Life Sciences in a report on Friday, August 9th.

Several hedge funds and other institutional investors have recently made changes to their positions in ACHV. Jane Street Group LLC purchased a new position in shares of Achieve Life Sciences during the 2nd quarter valued at about $32,000. Searle & CO. raised its holdings in shares of Achieve Life Sciences by 80.4% during the 2nd quarter. Searle & CO. now owns 132,592 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 59,092 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Achieve Life Sciences by 152.2% during the 2nd quarter. Vanguard Group Inc. now owns 274,519 shares of the biopharmaceutical company’s stock valued at $530,000 after buying an additional 165,667 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Achieve Life Sciences by 12.5% during the 2nd quarter. Renaissance Technologies LLC now owns 321,268 shares of the biopharmaceutical company’s stock valued at $620,000 after buying an additional 35,607 shares in the last quarter. Finally, Sio Capital Management LLC raised its holdings in shares of Achieve Life Sciences by 24.4% during the 2nd quarter. Sio Capital Management LLC now owns 524,413 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 102,934 shares in the last quarter. 18.63% of the stock is currently owned by institutional investors.

Shares of NASDAQ:ACHV traded up $0.03 on Thursday, hitting $1.58. The company’s stock had a trading volume of 59,495 shares, compared to its average volume of 118,429. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.62 and a current ratio of 3.62. Achieve Life Sciences has a 1 year low of $1.04 and a 1 year high of $4.63. The company has a 50-day simple moving average of $1.99 and a 200 day simple moving average of $2.69.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.

Read More: Growth Stocks

Get a free copy of the Zacks research report on Achieve Life Sciences (ACHV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit